To include your compound in the COVID-19 Resource Center, submit it here.

NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

NuCana plc (NASDAQ:NCNA) reported interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE